For instance, Belzutifan has been approved clinically as a second-generation specific HIF-2α inhibitor for patients with Von Hippel–Lindau (VHL) syndrome to treat associated clear cell renal carcinoma and central nervous system hemangioblastomas [173]. This evidence concerns the gene EPAS1 and von Hippel-Lindau disease.